Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients

Cancer Immunology, Immunotherapy

Volumn 61, Issue 2, 2012, Pages 169-179

  Wilkinson, Ray ^a,c   Woods, Katherine ^a   D'Rozario, Rachael ^a   Prue, Rebecca ^a   Vari, Frank ^a,d   Hardy, Melinda Y ^a   Dong, Ying ^b   Clements, Judith A ^b   Hart, Derek N J ^a,e   Radford, Kristen J ^a  

^a MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c QUEENSLAND HEALTH   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Cytotoxic T cells; Immunotherapy; Kallikrein; Prostate cancer; Tumor antigen

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; EPITOPE; HLA A ANTIGEN; KALLIKREIN 4; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SERINE PROTEINASE; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER PATIENT; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; MONOCYTE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY;

ADULT; AGED; ANTIGENS, NEOPLASM; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; DENDRITIC CELLS; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNODOMINANT EPITOPES; KALLIKREINS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; PROTEIN SORTING SIGNALS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84856763468     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1095-2     Document Type: Review

References (44)

1. A Vulink KJ Radford C Melief DN Hart 2008 Dendritic cells in cancer immunotherapy Adv Cancer Res 99 363 407 18037410 10.1016/S0065-230X(07)99006-5 1:CAS:528:DC%2BD1cXitlGqurk%3D (Pubitemid 350137256)
2. CG Drake 2010 Prostate cancer as a model for tumour immunotherapy Nat Rev Immunol 10 8 580 593 20651745 10.1038/nri2817 1:CAS:528:DC%2BC3cXpt1Gju78%3D
3. EJ Small PF Schellhammer CS Higano CH Redfern JJ Nemunaitis FH Valone SS Verjee LA Jones RM Hershberg 2006 Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 19 3089 3094 16809734 10.1200/JCO.2005.04.5252 1:CAS:528:DC%2BD28XnslKhs7g%3D (Pubitemid 46638945)
4. P Correale K Walmsley C Nieroda S Zaremba M Zhu J Schlom KY Tsang 1997 In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen J Natl Cancer Inst 89 4 293 300 9048833 10.1093/jnci/89.4.293 1:CAS:528:DyaK2sXhvVegsLo%3D (Pubitemid 27085891)
5. GP Murphy BA Tjoa SJ Simmons H Ragde M Rogers A Elgamal GM Kenny MJ Troychak ML Salgaller AL Boynton 1999 Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment Prostate 39 1 54 59 10221267 10.1002/(SICI)1097-0045(19990401) 39:1<54::AID-PROS9>3.0.CO;2-U 1:STN:280:DyaK1M3js1CmtA%3D%3D (Pubitemid 29143110)
6. PA Lodge LA Jones RA Bader GP Murphy ML Salgaller 2000 Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial Cancer Res 60 4 829 833 10706088 1:CAS:528:DC%2BD3cXhs1SiurY%3D (Pubitemid 30129509)
7. J Lu E Celis 2002 Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen Cancer Res 62 20 5807 5812 12384542 1:CAS:528:DC%2BD38XotFyktrc%3D (Pubitemid 35204739)
8. MV Peshwa JD Shi C Ruegg R Laus WC van Schooten 1998 Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide Prostate 36 2 129 138 9655265 10.1002/(SICI)1097-0045(19980701)36:2<129::AID- PROS8>3.0.CO;2-D 1:CAS:528:DyaK1cXksFSjtrk%3D (Pubitemid 28311317)
9. BM Olson TP Frye LE Johnson L Fong KL Knutson ML Disis DG McNeel 2010 HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase Cancer Immunol Immunother 59 6 943 953 20140431 10.1007/s00262-010-0820-6 1:CAS:528:DC%2BC3cXktFOjt7g%3D
10. K Khazaie A Bonertz P Beckhove 2009 Current developments with peptide-based human tumor vaccines Curr Opin Oncol 21 6 524 530 19770763 10.1097/CCO.0b013e328331a78e 1:CAS:528:DC%2BD1MXht1KjurvI
11. JA Clements NM Willemsen SA Myers Y Dong 2004 The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers Crit Rev Clin Lab Sci 41 3 265 312 15307634 10.1080/10408360490471931 1:CAS:528:DC%2BD2cXls1OlsLY%3D (Pubitemid 38888061)
12. PS Nelson L Gan C Ferguson P Moss R Gelinas L Hood K Wang 1999 Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression Proc Natl Acad Sci USA 96 6 3114 3119 10077646 10.1073/pnas.96.6.3114 1:CAS:528:DyaK1MXhvFykt70%3D (Pubitemid 29148853)
13. GM Yousef CV Obiezu LY Luo MH Black EP Diamandis 1999 Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated Cancer Res 59 17 4252 4256 10485467 1:CAS:528:DyaK1MXlvVSmsrg%3D (Pubitemid 29418738)
14. Stephenson SA, Verity K, Ashworth LK, Clements JA (1999) Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4. J Biol Chem 274 (33):23210-23214
15. JL Shaw EP Diamandis 2007 Distribution of 15 human kallikreins in tissues and biological fluids Clin Chem 53 8 1423 1432 17573418 10.1373/clinchem.2007. 088104 1:CAS:528:DC%2BD2sXosVKqs7g%3D (Pubitemid 47206338)
16. Z Xi TI Klokk K Korkmaz P Kurys C Elbi B Risberg H Danielsen M Loda F Saatcioglu 2004 Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer Cancer Res 64 7 2365 2370 15059887 10.1158/0008-5472.CAN-03-2025 1:CAS:528:DC%2BD2cXis1yjtL8%3D (Pubitemid 38523888)
17. Y Dong LT Bui DM Odorico OL Tan SA Myers H Samaratunga RA Gardiner JA Clements 2005 Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms Endocr Relat Cancer 12 4 875 889 16322328 10.1677/erc.1.01062 1:CAS:528:DC%2BD28XnvVyjtQ%3D%3D (Pubitemid 41815782)
18. TL Veveris-Lowe MG Lawrence RL Collard L Bui AC Herington DL Nicol JA Clements 2005 Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells Endocr Relat Cancer 12 3 631 643 16172196 10.1677/erc.1.00958 1:CAS:528:DC%2BD2MXht1Sjsr3L (Pubitemid 41482997)
19. TI Klokk A Kilander Z Xi H Waehre B Risberg HE Danielsen F Saatcioglu 2007 Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer Cancer Res 67 11 5221 5230 17545602 10.1158/0008-5472.CAN-06-4728 1:CAS:528:DC%2BD2sXmtVaisbY%3D (Pubitemid 46997260)
20. CH Day GR Fanger MW Retter BL Hylander RB Penetrante RL Houghton X Zhang PD McNeill AM Filho M Nolasco R Badaro MA Cheever SG Reed DC Dillon Y Watanabe 2002 Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera Oncogene 21 46 7114 7120 12370833 10.1038/sj.onc.1205786 1:CAS:528:DC%2BD38XnsFyltbw%3D (Pubitemid 35252985)
21. JA Hural RS Friedman A McNabb SS Steen RA Henderson M Kalos 2002 Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation J Immunol 169 1 557 565 12077288 1:CAS:528:DC%2BD38XltVKitr8%3D (Pubitemid 34686179)
22. KC Parker MA Bednarek JE Coligan 1994 Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains J Immunol 152 1 163 175 8254189 1:CAS:528:DyaK2cXhtlWlsLY%3D
23. H Rammensee J Bachmann NP Emmerich OA Bachor S Stevanovic 1999 SYFPEITHI: database for MHC ligands and peptide motifs Immunogenetics 50 3-4 213 219 10602881 10.1007/s002510050595 1:CAS:528:DyaK1MXntlalsbs%3D (Pubitemid 30099526)
24. KJ Radford CJ Turtle AJ Kassianos S Vuckovic D Gardiner D Khalil K Taylor S Wright D Gill DN Hart 2005 Immunoselection of functional CMRF-56 + blood dendritic cells from multiple myeloma patients for immunotherapy J Immunother 28 4 322 331 16000950 10.1097/01.cji.0000163592.66910.e4 1:CAS:528: DC%2BD2MXlvVCisrc%3D (Pubitemid 40962325)
25. GA Rabinovich D Gabrilovich EM Sotomayor 2007 Immunosuppressive strategies that are mediated by tumor cells Annu Rev Immunol 25 267 296 17134371 10.1146/annurev.immunol.25.022106.141609 1:CAS:528:DC%2BD2sXltlagu7c%3D (Pubitemid 46697910)
26. KL Bondurant MD Crew AD Santin TJ O'Brien MJ Cannon 2005 Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme Clin Cancer Res 11 9 3446 3454 15867247 10.1158/1078-0432. CCR-04-2043 1:CAS:528:DC%2BD2MXjslOqtL8%3D (Pubitemid 40627899)
27. ML Wei P Cresswell 1992 HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides Nature 356 6368 443 446 1557127 10.1038/356443a0 1:CAS:528:DyaK38XitFamtr4%3D
28. Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella E, Hunt DF, Engelhard VH (1992) HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 255(5049):1264-1266
29. F El Hage V Stroobant I Vergnon JF Baurain H Echchakir V Lazar S Chouaib PG Coulie F Mami-Chouaib 2008 Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome- independent pathway Proc Natl Acad Sci USA 105 29 10119 10124 18626012 10.1073/pnas.0802753105 1:CAS:528:DC%2BD1cXptFOgsrs%3D
30. T Wolfel A Van Pel V Brichard J Schneider B Seliger KH Meyer zum Buschenfelde T Boon 1994 Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes Eur J Immunol 24 3 759 764 8125142 10.1002/eji.1830240340 1:STN:280:DyaK2c7ntVymtw%3D%3D (Pubitemid 24076646)
31. C Wolfel I Drexler A Van Pel T Thres N Leister W Herr G Sutter C Huber T Wolfel 2000 Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope Int J Cancer 88 3 432 438 11054673 10.1002/1097-0215(20001101)88:3<432::AID-IJC16>3.0.CO;2-9 1:CAS:528:DC%2BD3cXnsFWntbo%3D
32. I Correa T Plunkett J Coleman E Galani E Windmill JM Burchell J Taylor-Papdimitriou 2005 Responses of human T cells to peptides flanking the tandem repeat and overlapping the signal sequence of MUC1 Int J Cancer 115 5 760 768 15729696 10.1002/ijc.20949 1:CAS:528:DC%2BD2MXkvF2ks7c%3D (Pubitemid 40776700)
33. S Oh M Terabe CD Pendleton A Bhattacharyya TK Bera M Epel Y Reiter J Phillips WM Linehan C Kasten-Sportes I Pastan JA Berzofsky 2004 Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells Cancer Res 64 7 2610 2618 15059918 10.1158/0008-5472.CAN-03-2183 1:CAS:528:DC%2BD2cXis1yju7w%3D (Pubitemid 38523919)
34. J Dannull PA Diener L Prikler G Furstenberger T Cerny U Schmid DK Ackermann M Groettrup 2000 Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer Cancer Res 60 19 5522 5528 11034097 1:CAS:528:DC%2BD3cXns1eht70%3D
35. S Thomas HJ Stauss EC Morris 2010 Molecular immunology lessons from therapeutic T-cell receptor gene transfer Immunology 129 2 170 177 20561357 10.1111/j.1365-2567.2009.03227.x 1:CAS:528:DC%2BC3cXht1ert70%3D
36. V Appay DC Douek DA Price 2008 CD8 + T cell efficacy in vaccination and disease Nat Med 14 6 623 628 18535580 10.1038/nm.f.1774 1:CAS:528: DC%2BD1cXmvVCnsbc%3D (Pubitemid 351809548)
37. Y Dong A Kaushal L Bui S Chu PJ Fuller J Nicklin H Samaratunga JA Clements 2001 Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas Clin Cancer Res 7 8 2363 2371 11489814 1:CAS:528:DC%2BD3MXmsVOmt7Y%3D (Pubitemid 32751637)
38. B Davidson Z Xi TI Klokk CG Trope A Dorum M Scheistroen F Saatcioglu 2005 Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions Am J Clin Pathol 123 3 360 368 15716231 10.1309/PTBB5BPCKX8K9V69 1:CAS:528:DC%2BD2MXis1Kjs78%3D (Pubitemid 40315076)
39. A Mange C Desmetz ML Berthes T Maudelonde J Solassol 2008 Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells Biochem Biophys Res Commun 375 1 107 112 18687310 10.1016/j.bbrc.2008.07. 138 1:CAS:528:DC%2BD1cXhtVOit7zM
40. B Zhang 2008 Targeting the stroma by T cells to limit tumor growth Cancer Res 68 23 9570 9573 19047130 10.1158/0008-5472.CAN-08-2414 1:CAS:528: DC%2BD1cXhsVegtb3K
41. J Hombach H Pircher S Tonegawa RM Zinkernagel 1995 Strictly transporter of antigen presentation (TAP)-dependent presentation of an immunodominant cytotoxic T lymphocyte epitope in the signal sequence of a virus protein J Exp Med 182 5 1615 1619 7595234 10.1084/jem.182.5.1615 1:CAS:528:DyaK2MXovFWqsb4%3D
42. MC Wolkers N Brouwenstijn AH Bakker M Toebes TN Schumacher 2004 Antigen bias in T cell cross-priming Science 304 5675 1314 1317 15166378 10.1126/science.1096268 1:CAS:528:DC%2BD2cXkt1Ggu7s%3D (Pubitemid 38697426)
43. P Brossart S Wirths G Stuhler VL Reichardt L Kanz W Brugger 2000 Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells Blood 96 9 3102 3108 11049990 1:CAS:528:DC%2BD3cXnslGnt7w%3D
44. M Avgeris K Mavridis A Scorilas 2010 Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies Biol Chem 391 5 505 511 20302518 10.1515/BC.2010.056 1:CAS:528:DC%2BC3cXmtVWmtr0%3D